| # | Title | Journal | Year | Citations |
|---|
| 1 | Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: Report of the BIOMED-2 Concerted Action BMH4-CT98-3936 | Leukemia | 2003 | 2,788 |
| 2 | International uniform response criteria for multiple myeloma | Leukemia | 2006 | 2,332 |
| 3 | Embryonic stem cell-derived microvesicles reprogram hematopoietic progenitors: evidence for horizontal transfer of mRNA and protein delivery | Leukemia | 2006 | 1,405 |
| 4 | Standardization and quality control studies of ‘real-time’ quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia – A Europe Against Cancer Program | Leukemia | 2003 | 1,359 |
| 5 | Landscape of genetic lesions in 944 patients with myelodysplastic syndromes | Leukemia | 2014 | 1,291 |
| 6 | The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms | Leukemia | 2022 | 1,211 |
| 7 | Membrane-derived microvesicles: important and underappreciated mediators of cell-to-cell communication | Leukemia | 2006 | 1,208 |
| 8 | Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients | Leukemia | 2014 | 1,128 |
| 9 | γH2AX: a sensitive molecular marker of DNA damage and repair | Leukemia | 2010 | 1,078 |
| 10 | Involvement of PI3K/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: a target for cancer chemotherapy | Leukemia | 2003 | 1,055 |
| 11 | Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease | Leukemia | 1999 | 1,038 |
| 12 | The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms | Leukemia | 2022 | 1,023 |
| 13 | Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma | Leukemia | 2009 | 1,000 |
| 14 | Classification and diagnosis of myeloproliferative neoplasms: The 2008 World Health Organization criteria and point-of-care diagnostic algorithms | Leukemia | 2008 | 908 |
| 15 | Internal tandem duplication of the flt3 gene found in acute myeloid leukemia | Leukemia | 1996 | 903 |
| 16 | MSC-derived exosomes: a novel tool to treat therapy-refractory graft-versus-host disease | Leukemia | 2014 | 888 |
| 17 | European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia | Leukemia | 2020 | 875 |
| 18 | Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy | Leukemia | 2002 | 839 |
| 19 | Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia | Leukemia | 2009 | 808 |
| 20 | Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using ‘real-time’ quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) – a Europe against cancer program | Leukemia | 2003 | 806 |
| 21 | Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma | Leukemia | 2008 | 787 |
| 22 | International Myeloma Working Group molecular classification of multiple myeloma: spotlight review | Leukemia | 2009 | 775 |
| 23 | EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes | Leukemia | 2012 | 738 |
| 24 | The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells | Leukemia | 2000 | 720 |
| 25 | International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders | Leukemia | 2009 | 686 |
| 26 | Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial | Leukemia | 2016 | 685 |
| 27 | Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management | Leukemia | 2010 | 677 |
| 28 | Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia | Leukemia | 2004 | 674 |
| 29 | Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide | Leukemia | 2012 | 668 |
| 30 | EuroFlow standardization of flow cytometer instrument settings and immunophenotyping protocols | Leukemia | 2012 | 668 |
| 31 | Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study | Leukemia | 2012 | 664 |
| 32 | Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo | Leukemia | 2016 | 658 |
| 33 | Mutations and prognosis in primary myelofibrosis | Leukemia | 2013 | 653 |
| 34 | A population of very small embryonic-like (VSEL) CXCR4+SSEA-1+Oct-4+ stem cells identified in adult bone marrow | Leukemia | 2006 | 647 |
| 35 | Signal transduction mediated by the Ras/Raf/MEK/ERK pathway from cytokine receptors to transcription factors: potential targeting for therapeutic intervention | Leukemia | 2003 | 632 |
| 36 | Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data | Leukemia | 2007 | 626 |
| 37 | Targeting FLT3 mutations in AML: review of current knowledge and evidence | Leukemia | 2019 | 625 |
| 38 | Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents | Leukemia | 2014 | 602 |
| 39 | JAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle progression and leukemogenesis | Leukemia | 2004 | 601 |
| 40 | Myeloid sarcoma: clinico-pathologic, phenotypic and cytogenetic analysis of 92 adult patients | Leukemia | 2007 | 571 |
| 41 | The immunological profile of B-cell disorders and proposal of a scoring system for the diagnosis of CLL | Leukemia | 1994 | 551 |
| 42 | Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study | Leukemia | 2013 | 540 |
| 43 | Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications | Leukemia | 2001 | 536 |
| 44 | Characterization of a human cell line (NK-92) with phenotypical and functional characteristics of activated natural killer cells | Leukemia | 1994 | 535 |
| 45 | The MLL recombinome of acute leukemias in 2017 | Leukemia | 2018 | 527 |
| 46 | Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity | Leukemia | 2018 | 525 |
| 47 | Primary murine MSC show highly efficient homing to the bone marrow but lose homing ability following culture | Leukemia | 2003 | 521 |
| 48 | Clinical use of lentiviral vectors | Leukemia | 2018 | 519 |
| 49 | HMG-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apoptosis | Leukemia | 2002 | 507 |
| 50 | Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma | Leukemia | 2010 | 505 |
